ERBB2 and breast cancer: Compared to patients with ES-TNBC, patients with LA-HR+/HER2- BC had a 63% relative increased risk of death after adjusting for all covariates (HR = 1.63; 95% CI 1.53–1.73; p < 0.0001) (Figure 1a).